Development of a diagnostic support system for the fibrosis of nonalcoholic fatty liver disease using artificial intelligence and deep learning

Liver fibrosis is a pathological condition characterized by the abnormal proliferation of liver tissue, subsequently able to progress to cirrhosis or possibly hepatocellular carcinoma. The development of artificial intelligence and deep learning have begun to play a significant role in fibrosis detection. This study aimed to develop SMART AI‐PATHO, a fully automated assessment method combining quantification of histopathological architectural features, to analyze steatosis and fibrosis in nonalcoholic fatty liver disease (NAFLD) core biopsies and employ Metavir fibrosis staging as standard references and fat assessment grading measurement for comparison with the pathologist interpretations. There were 146 participants enrolled in our study. The correlation of Metavir scoring system interpretation between pathologists and SMART AI‐PATHO was significantly correlated (Agreement = 68%, Kappa = 0.59, p‐value <0.001), which subgroup analysis of significant fibrosis (Metavir score F2‐F4) and nonsignificant fibrosis (Metavir score F0‐F1) demonstrated substantial correlated results (agreement = 80%, kappa = 0.61, p‐value <0.001), corresponding with the correlation of advanced fibrosis (Metavir score F3‐F4) and nonadvanced fibrosis groups (Metavir score F0‐F2), (agreement = 89%, kappa = 0.74, p‐value <0.001). SMART AI‐PATHO, the first pivotal artificially intelligent diagnostic tool for the color‐based NAFLD hepatic tissue staging in Thailand, demonstrated satisfactory performance as a pathologist to provide liver fibrosis scoring and steatosis grading. In the future, developing AI algorithms and reliable testing on a larger scale may increase accuracy and contribute to telemedicine consultations for general pathologists in clinical practice.